CI Agent - Clinical Trials Updates

Client Selection

Select Client

View Type

Filter Clinical Trials

Advanced Filters

Update Type

Phase

Sponsor

Date Range

Clinical Trial Updates from ClinicalTrials.gov

Sort by:

Trial ID	Title	Sponsor	Disease State	Phase	Update Type	Date	Actions
NCT05123456	Phase 3 Study of Novel Anti-BCMA Therapy in Multiple Myeloma	Pfizer	Multiple Myeloma	Phase 3	New Trial	May 28, 2025	View
NCT04987654	Study of IL-23 Inhibitor in Psoriatic Arthritis	Novartis	Psoriatic Arthritis	Phase 3	Status Change	May 27, 2025	View
NCT03456789	Long-term Safety Study of Treatment in Moderate-to-Severe Psoriasis	AstraZeneca	Psoriasis	Phase 4	Results Posted	May 26, 2025	View
NCT05789012	Phase 2 Study of NMDA Receptor Modulator in Treatment-Resistant Depression	Merck	Treatment-Resistant Depression	Phase 2	New Trial	May 25, 2025	View
NCT04567890	Study of Novel CDK4/6 Inhibitor in HR+/HER2- Breast Cancer	Pfizer	Breast Cancer	Phase 2	Enrollment Update	May 24, 2025	View
NCT03210987	Phase 3 Study of PARP Inhibitor in Prostate Cancer	AstraZeneca	Prostate Cancer	Phase 3	Results Posted	May 23, 2025	View
NCT05432109	Study of Anti-IL-17 Antibody in Psoriasis	Novartis	Psoriasis	Phase 2	Status Change	May 22, 2025	View
NCT04876543	Phase 1 Study of Novel Bispecific Antibody in Multiple Myeloma	Roche	Multiple Myeloma	Phase 1	New Trial	May 21, 2025	View

Showing 1-8 of 42 trial updates

Trial Details: NCT05123456

Phase 3 Study of Novel Anti-BCMA Therapy in Multiple Myeloma

A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Novel Anti-BCMA Therapy Compared to Standard of Care in Subjects with Relapsed/Refractory Multiple Myeloma

Sponsor

Pfizer

Phase

Phase 3

Status

Recruiting

Study Type

Interventional

Start Date

May 28, 2025

Primary Completion Date

December 15, 2027

Enrollment

450 participants

Locations

120 study locations

Primary Outcome Measures

Progression-Free Survival (PFS) [Time Frame: Up to 36 months]
Overall Response Rate (ORR) [Time Frame: Up to 36 months]

Secondary Outcome Measures

Overall Survival (OS) [Time Frame: Up to 60 months]
Duration of Response (DOR) [Time Frame: Up to 36 months]
Time to Response (TTR) [Time Frame: Up to 12 months]
Minimal Residual Disease (MRD) negativity rate [Time Frame: Up to 36 months]

Eligibility Criteria

Inclusion Criteria:

Adults ≥ 18 years of age
Confirmed diagnosis of multiple myeloma
Relapsed or refractory disease after at least 2 prior lines of therapy
Prior exposure to a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody

Exclusion Criteria:

Prior BCMA-targeted therapy
Known CNS involvement
Significant cardiovascular disease
Active infection requiring systemic treatment